Buy Ulipristal Acetate Powder (26784-99-4) hplc≥98% | AASraw
AASraw produces Cannabidiol(CBD) powder and Hemp Essential Oil in bulk!

Ulipristal Acetate Powder (26784-99-4)

Rating: SKU: 26784-99-4. Category:

AASraw is with synthesis and production ability from gram to mass order of Ulipristal Acetate Powder (26784-99-4), under CGMP regulation and trackable quality control system.

Product Description


Ulipristal Acetate Powder (26784-99-4) video




Ulipristal Acetate Powder (26784-99-4) Specification:

Chemical Structure: Product Name: Ulipristal Acetate(Ulipristal Acetate intermediate)
Cas No.: 26784-99-4/126690-41-3/54201-84-2
Molecular Formula: C30H37NO4
Molecular Weight: 475.62
Synonyms: 3,20-bis-Ethylenedioxy-5α,17α-dihydroxy-11β-(4-N,N-dimethylaminopheynl)-19-norpregn-9-ene; 3,20-bis-Ethylenedioxy-19-norpregna-5(10)9(11)dien-17-ol
Storage: Store at room temperature away from light and moisture.
Documents(COA & HPLC etc.): Available


Ulipristal Acetate Powder (26784-99-4) Description:

Ulipristal acetate was approved for medical use in the United States in 2010.It is on the World Health Organization’s List of Essential Medicines, the most effective and safe medicines needed in a health system.In the United Kingdom it costs the NHS about 17 pounds per course of emergency birth control of 2015.To improve access, some recommend all who can get pregnant be given a prescription for use if needed.

Ulipristal acetate powder belongs to selective progesterone receptor modulators, antagonistic and agonistic effect on progesterone receptor. It and the body of progesterone receptor binding to prevent progesterone and progesterone receptors. Acetic acid of his efficacy depends on our delivery time in the menstrual cycle. Delivery in mid follicular hyperplasia may inhibit folliculogenesis and reduce the concentration of estradiol. Administration of luteinizing hormone peak in the follicles of delayed rupture in 5 ~ 9 days. Corpus luteum of early administration of not obvious delay of endometrial maturation, but can make the endometrial thickness reduction of 0.6 ± 2.2mm (mean ± SD).



  • British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. pp. 510, 560. ISBN 9780857111562.
  • Trussell, James; Raymond, Elizabeth G.; Cleland, Kelly (2014). “Emergency Contraception: A Last Chance to Prevent Unintended Pregnancy” (PDF). Contemporary Readings in Law and Social Justice. 6 (2): 7–38. Archived (PDF) from the original on 23 September 2010.
  • HRA Pharma (March 2013). “Countries where ellaOne was launched”. Paris: HRA Pharma. Archived from the original on 28 July 2013. Retrieved 25 March 2014.